MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma

Statistical significance in overall survival benefit was achieved in patients aged 65 and under.

  • By

  • October 7, 2026

  • 7 min

Share

Original Source(s)

MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma

  • by

  • October 7, 2026

Related Content

Longitudinal spatial changes of the contralesional corticospinal tract in high-grade glioma: a within-patient DTI tractography study

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia